CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01270438
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:37.385034+00:00
Published At: 2017-04-04T00:00:00+00:00
Record Updated At: 2017-04-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-04-04"
protocolSection.identificationModule.nctId: "NCT01270438"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.